Advertisement
CLLS vs SLN
Which Stock Would AI Choose? Cellectis S.A. (CLLS) vs. Silence Therapeutics plc (SLN) Stock Comparison
Key Takeaways
- Cellectis (CLLS) is pivoting away from allogeneic CAR-T cancer therapies toward in-vivo gene editing for cardiovascular disease, a strategic shift that triggered a sharp selloff and analyst downgrades.
- Silence Therapeutics (SLN) agreed to be acquired by Germany's Merck KGaA for $20 per ADS in cash, an all-cash deal valued at about $1.3 billion that sent shares up roughly 125%.
- The two stocks now represent fundamentally different risk profiles: CLLS is a speculative clinical-stage biotech, while SLN has become a merger-arbitrage situation trading near its fixed acquisition price.
- Relative performance has diverged dramatically in recent weeks, with CLLS under pressure from pipeline uncertainty while SLN is anchored by a definitive takeover bid.
- CLLS extended its cash runway into the second half of 2028, while SLN's deal is expected to close in the first quarter of 2027, pending shareholder, court, and regulatory approvals.
- For ongoing coverage of these companies, explore CLLS Major News, CLLS Today's Price Move, SLN Major News, and SLN Today's Price Move.
- To see how automated systems are currently positioning across the market, browse the Trending AI Robots.
Introduction
Biotechnology stocks can produce dramatic swings in both directions, and the recent trajectories of Cellectis (CLLS) and Silence Therapeutics (SLN) illustrate that contrast vividly. One is a French gene-editing specialist navigating a major strategic repositioning, while the other is a UK-based RNA-interference (RNAi) developer being absorbed in a premium takeover. This stock comparison is most relevant for traders and investors who track clinical-stage biotech, merger-driven price action, and shifting market sentiment. Understanding the distinct catalysts driving each name—a pipeline pivot versus a definitive acquisition—helps clarify their relative performance, risk profiles, and market positioning in the current environment.
CLLS Overview and Recent Performance
CLLS is Cellectis S.A., a Paris-based clinical-stage biotechnology company built around its TALEN gene-editing platform. Historically known for "off-the-shelf" allogeneic CAR-T cell therapies (treatments using donor immune cells engineered to attack cancer), the company recently announced a major strategic shift. Cellectis is discontinuing development of its lead blood-cancer programs, lasme-cel and eti-cel, and refocusing on in-vivo gene editing aimed at cardiovascular risk factors, with lead programs HEAL-101 (targeting very high triglycerides) and HEAL-201 (targeting lipoprotein, or "bad," cholesterol).
The pivot unsettled investors. CLLS shares fell more than 40% in a single session following the announcement, and the stock was downgraded by at least one research firm citing delayed catalysts pushed out to late 2027 and 2028. While the restructuring is expected to extend the company's cash runway into the second half of 2028, near-term clinical catalysts have been pushed further out. Existing partnerships with companies such as AstraZeneca, Allogene Therapeutics, and Iovance Biotherapeutics continue, but sentiment has been weighed down by the loss of nearer-term cancer programs and the extended timeline to any potential approval.
SLN Overview and Recent Performance
SLN is Silence Therapeutics plc, a London-based biotechnology company focused on siRNA (small interfering RNA) therapies—molecules that silence disease-causing genes. Its lead asset, divesiran, is being developed for polycythemia vera, a rare blood cancer characterized by excess red blood cell production, and has reported potentially best-in-class Phase 2 data.
In recent weeks, Silence agreed to be acquired by Merck KGaA (the German life-science company, distinct from U.S.-based Merck & Co.) in an all-cash transaction valued at approximately $1.3 billion in equity, or $20 per American depositary share (ADS). The offer represented a roughly 130% premium to the prior closing price and about an 82% premium to the 30-day volume-weighted average. SLN shares surged more than 120% on the news and now trade within a few percentage points of the offer price, reflecting market expectations that the deal will close in the first quarter of 2027. Analysts largely downgraded the stock to neutral or market-perform ratings, since the fixed cash offer effectively caps near-term upside.
Trending AI Robots
For traders seeking a systematic perspective on names like these, Tickeron's Trending AI Robots page curates a select group of AI-driven trading bots from a much larger universe of hundreds of automated systems that trade thousands of different tickers. Only the bots best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and target ticker sets, giving users a broad view of how automated approaches are navigating the market. Because each bot differs in methodology and risk profile, the curated list offers a practical starting point for evaluating systematic tools rather than a one-size-fits-all signal. Explore the Trending AI Robots section to review current selections and their characteristics.
Head-to-Head Comparison
The clearest contrast between these two companies is the nature of their current catalysts. CLLS remains an independent, pre-revenue biotech whose value hinges on the execution of a newly repositioned pipeline with catalysts years away. Its risk is concentrated in scientific and clinical execution, and its stock has exhibited significant downside volatility as the market reprices that uncertainty. In contrast, SLN has transformed from a clinical-stage investment into a merger-arbitrage situation, with its price pinned near a fixed $20 cash offer and remaining upside limited to a small spread before the expected close.
The two names also differ in sector exposure and growth drivers. Cellectis is tied to gene editing and future cardiovascular applications, while SLN's near-term value is now defined by a single acquisition transaction rather than its broader siRNA pipeline. Risk factors diverge as well: CLLS faces clinical-timeline and funding risks, whereas SLN faces deal-completion risk, including shareholder, court, and regulatory approvals. On market sentiment, SLN has benefited from a premium bid that validates its lead asset, while CLLS has contended with downgrades and a re-rating of its pipeline value.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalysts, Tickeron's AI would likely favor SLN in the current environment. The stock's price action is supported by a definitive, premium cash acquisition that anchors its value near a fixed level, providing greater short-term stability and a clear, near-term catalyst in the form of an anticipated closing in the first quarter of 2027. By comparison, CLLS carries heavier uncertainty around a repositioned pipeline with delayed data readouts, which tends to weigh on trend consistency. This assessment is probabilistic rather than definitive: it reflects relative positioning at a moment when SLN's outcome is largely contractual while CLLS's remains dependent on years of clinical execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Buy and SLN is a Buy.
CLLS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLLS's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CLLS as a result. In 69 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +30.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 48 cases where CLLS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.551) is normal, around the industry mean (3.104). P/E Ratio (-1.625) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SLN in +0.61% Uptrend, growing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SLN advanced for three days, in 242 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on SLN as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for SLN just turned positive on October 19, 2026. Looking at past instances where SLN's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
SLN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SLN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SLN broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.924) is normal, around the industry mean (3.104). P/E Ratio (-15.318) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLLS | SLN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 92 | 34 | |
P/E GROWTH RATING 1..100 | 8 | 96 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLLS's Valuation (61) in the Biotechnology industry is in the same range as SLN (90) in the null industry. This means that CLLS’s stock grew similarly to SLN’s over the last 12 months.
CLLS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLN (100) in the null industry. This means that CLLS’s stock grew similarly to SLN’s over the last 12 months.
CLLS's SMR Rating (98) in the Biotechnology industry is in the same range as SLN (98) in the null industry. This means that CLLS’s stock grew similarly to SLN’s over the last 12 months.
SLN's Price Growth Rating (34) in the null industry is somewhat better than the same rating for CLLS (92) in the Biotechnology industry. This means that SLN’s stock grew somewhat faster than CLLS’s over the last 12 months.
CLLS's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for SLN (96) in the null industry. This means that CLLS’s stock grew significantly faster than SLN’s over the last 12 months.
| CLLS | SLN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| Advances ODDS (%) | 7 days ago 79% | 9 days ago 89% |
| Declines ODDS (%) | 2 days ago 89% | 22 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 1 FA rating(s) are green while SLN’s FA Score has 0 green FA rating(s).
- CLLS’s FA Score: 1 green, 4 red.
- SLN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 5 TA indicator(s) are bullish while SLN’s TA Score has 5 bullish TA indicator(s).
- CLLS’s TA Score: 5 bullish, 3 bearish.
- SLN’s TA Score: 5 bullish, 5 bearish.
Price Growth
CLLS (@Biotechnology) experienced а +7.60% price change this week, while SLN (@Biotechnology) price change was -0.10% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.
Reported Earning Dates
CLLS is expected to report earnings on Nov 06, 2026.
SLN is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SLN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLN has been loosely correlated with IRON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SLN jumps, then IRON could also see price increases.
| Ticker / NAME | Correlation To SLN | 1D Price Change % | ||
|---|---|---|---|---|
| SLN | 100% | +0.05% | ||
| IRON - SLN | 53% Loosely correlated | -2.75% | ||
| CLLS - SLN | 43% Loosely correlated | -3.70% | ||
| RCUS - SLN | 37% Loosely correlated | -1.87% | ||
| TSHA - SLN | 35% Loosely correlated | -3.15% | ||
| ARQT - SLN | 33% Poorly correlated | -2.53% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DUG | 12.87 | 0.95 | +7.97% |
| ProShares UltraShort Energy (DUG) | |||
| TMF | 30.05 | 0.20 | +0.67% |
| Direxion Daily 20+ Year Treasury Bull 3X ETF (TMF) | |||
| VUSV | 72.44 | 0.29 | +0.40% |
| Vanguard Wellington U.S. Value Active ETF (VUSV) | |||
| CGUI | 25.24 | N/A | N/A |
| Capital Group Ultra Short Income ETF (CGUI) | |||
| SAWG | 24.25 | -0.06 | -0.24% |
| AAM Sawgrass US Large Cap Quality Growth ETF (SAWG) | |||